|
|
HIV Update 2002 (8) - AugustPublished by: Datamonitor Published: Oct. 22, 2002 - 19 Pages Table of ContentsOverview Introduction The monthly HIV update provides Datamonitor's assessment of the key market events that took place during August 2002. Key events include new product launches, clinical trial data and conference findings. Scope Key events are analyzed in the HIV market during August Coverage includes emerging market headlines, R&D pipeline data, epidemiology and disease specific factors Report Highlights The generics industry will play a significant role in the provision of cheap antiretrovirals to the developing world. Generics manufacturers such as Cipla are seeking to consolidate their positions within their own markets, but also extending their services to developing nations that favour low cost antiretrovirals. HIV resistance continues to increase at an alarming rate.One of the major hurdles for HIV drug manufacturers is the frequent mutation rate of HIV once infection occurs. Current drugs are simply not able to cope with the huge numbers of strain variants within the infected population. Pipeline drugs hold some promise in combating the situation, but only in the short term. Reasons to Purchase Stay informed of all of the important market led events taking place in the HIV market Gain insight into the likely market impact of the events that took place in August 2002 in the HIV market. DRIVERS AND TRENDS The generics industry will play a significant role in the provision of cheap antiretrovirals to the developing world Renewed strategies to fight the battle against HIV with antiretroviral therapy HIV resistance continues to increase at an alarming rate COMPANY HEADLINES A summary of the latest events from a company perspective Cipla May Supply South Africa with Generic Triple Drug Therapy RESEARCH AND DEVELOPMENT HEADLINES A summary of the key events from a pipeline drug perspective T-20 Effective in HIV-Positive Children Tat-Based Vaccine to Begin Phase III Trials Resistance to Fuzeon Rare in Primary HIV Isolates Triple Drug Therapy with Saquinavir Effective in HIV-Positive Pregnant Women DISEASE SPECIFIC HEADLINES An overview of the epidemiological, research and clinical perspective Eradication of HIV Epidemic Solely Through HAART Resistance Against Viramune in HIV-Positive Pregnant Women Sustained HIV Viral Rebound Linked to Intermittent Viremia Episodes Higher Levels of Anti-gp120 Antibody Associated with Faster Disease Progression HIV Resistance Increasing at Alarming Rate EBV Load Not Predictive Of AIDS Related NHL Development Depression Adversely Affects Adherence to HAART in HIVPositive Women Continued HAART Treatment Beneficial for Patients with Low CD4 Levels Oral Valganciclovir Option for CMV Retinitis in HIV patients Risk of Virus Transmission Through Transfusion Declines Broad Spectrum Neutralization by Sera Raised Against gp120-CD4 Complexes HAART Plus Cytotoxic Chemotherapy May Eliminate Viral Reservoirs Use of Alternative Medicines Common in HIV-infected Individuals EMERGING MARKETS HEADLINES A summary of the key events from the emerging markets Cuban HIV Isolates Show High Diversity Adolescent HIV Prevention Program Acceptable in Sub-Saharan Africa AbstractIntroduction: The monthly HIV update provides Datamonitor's assessment of the key market events that took place during August 2002. Key events include new product launches, clinical trial data and conference findings. Scope: * Key events are analyzed in the HIV market during August * Coverage includes emerging market headlines, R&D pipeline data, epidemiology and disease specific factors. Report Highlights: The generics industry will play a significant role in the provision of cheap antiretrovirals to the developing world. Generics manufacturers such as Cipla are seeking to consolidate their positions within their own markets, but also extending their services to developing nations that favour low cost antiretrovirals. HIV resistance continues to increase at an alarming rate.One of the major hurdles for HIV drug manufacturers is the frequent mutation rate of HIV once infection occurs. Current drugs are simply not able to cope with the huge numbers of strain variants within the infected population. Pipeline drugs hold some promise in combating the situation, but only in the short term. Reasons to Purchase: * Stay informed of all of the important market led events taking place in the HIV market * Gain insight into the likely market impact of the events that took place in August 2002 in the HIV market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||